Etrasimod: clinical trials recruiting now
4
Recruiting trials
2
Conditions studied
17
US states with sites
12
Countries
FDA drug label
- FDA-approved
- Yes. Etrasimod appears in the FDA drug-label database. Marketed as Velsipity.
FDA-approved use
VELSIPITY is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults. VELSIPITY is a sphingosine 1-phosphate receptor modulator indicated for the treatment of moderately to severely active ulcerative colitis in adults. ( 1 )
Phase breakdown
Phase 2 2
Not applicable 2
Conditions being studied
| Condition | Trials |
|---|---|
| Ulcerative Colitis · Etrasimod for Ulcerative Colitis | 4 |
| Colitis, Ulcerative · Etrasimod for Colitis, Ulcerative | 3 |
Recruiting trials involving Etrasimod
- A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
- A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
- A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
- An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
Common questions
Is Etrasimod FDA-approved?
Yes, marketed as Velsipity.
How many recruiting trials involve Etrasimod?
4 recruiting trials across 2 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.